I am focusing on the negatives because the negatives reveal serious issues with the design of the clinical trial and if there even is a viable market for the drug. Nobody in management seems to be taking responsibility for IXC ending up in this position. Who designed the trial? Who was monitoring the competition?
I have had IXC on my watch list for sometime and nearly bought a few weeks ago when the SP got down to 37c, but luckily for me my buy order wasn't reached. I will continue to watch IXC as the science is compelling, but I won't be buying in until we have some clarity on the path forward.
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-61
-
- There are more pages in this discussion • 164 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable